跳至主要内容
临床试验/EUCTR2012-004436-36-DK
EUCTR2012-004436-36-DK进行中(未招募)1 期

A prospective pilotstudy of immunological and radiological effects of intrathecal rituximab in patients with secondary progressive multiple sclerosis

Odense University Hospital0 个研究点目标入组 15 人开始时间: 2013年4月22日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
15

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Clinical definate multiple sclerosis
  • Secondary progressive multiple sclerosis defines as no relaps within 1 year, and sustained progression more than 3 month
  • Disease duration >15 years
  • EDSS score 3-7 (both included)
  • No contrast enhancement on MRI
  • Presence of oligoclonal bands and increased intrathechal IgG index
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 15
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Pregnancy and lactation
  • Positive anti-JC virus antibody
  • Treatment with Natalizumab within 6 month
  • Treatment with interferon-beta or glatiramer acetate within 3 month
  • Prior treatment with immunosupressant
  • Decreased leucocyte or platelet count
  • Decreased liver or kidneyfunction
  • B-cell deficiency (low IgA, IgG or IgM)
  • Implanted metal or devices that contraindicates MRI

研究者

相似试验